Research
Bifidobacterium animalis
11 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study.
RCT of 58 participants with metabolic syndrome risk factors comparing probiotics Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 to placebo over 12 weeks. The probiotics group showed significant reductions in LDL-cholesterol, body weight, BMI, waist circumference, systolic blood pressure, and total cholesterol, along with changes in gut microbiota diversity.
Immune status, well-being and gut microbiota in military supplemented with synbiotic ice cream and submitted to field training: a randomised clinical trial.
RCT evaluating synbiotic ice cream supplementation in 65 military participants during field training. Synbiotic ice cream containing inulin, L. acidophilus LA-5, and B. animalis BB-12 improved gut microbiota and reduced tenseness and sleepiness, but did not affect salivary IgA or gastrointestinal symptoms.
Starter formula enriched in prebiotics and probiotics ensures normal growth of infants and promotes gut health: a randomized clinical trial.
RCT of 413 infants comparing a formula enriched with bovine milk-derived oligosaccharides and B. lactis to a control formula. The enriched formula supported normal growth, was well tolerated, and improved intestinal health markers, but showed no significant difference in diarrhea and febrile infection incidence.
Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma.
RCT assessing the impact of a Bifidobacterium-containing yogurt product on the gut microbiome and clinical outcomes in mRCC patients undergoing VEGF-TKI therapy. Probiotic supplementation increased Bifidobacterium spp. levels, but clinical benefit rates were similar between probiotic-supplemented and probiotic-restricted arms.
Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.
This 24-week randomized controlled trial investigated the effects of synbiotic yogurt on hepatic steatosis and liver enzymes in 102 patients with NAFLD. The synbiotic group showed significant improvements in liver steatosis and enzyme concentrations compared to the conventional yogurt and control groups.
The Influence of a Bifidobacterium animalis Probiotic on Gingival Health: A Randomized Controlled Clinical Trial.
RCT evaluating the effect of yogurt supplemented with Bifidobacterium animalis on gingival health in 51 patients. After a 5-day non-brushing period, the probiotic group showed significantly better results in plaque index, gingival index, bleeding on probing, gingival crevicular fluid volume, and IL-1β levels compared to the control group.
Tolerance and safety of Lactobacillus paracasei ssp. paracasei in combination with Bifidobacterium animalis ssp. lactis in a prebiotic-containing infant formula: a randomised controlled trial.
RCT evaluating the safety and tolerance of a prebiotic-containing infant formula supplemented with Lactobacillus paracasei and Bifidobacterium animalis in 126 newborns. The probiotics group showed softer and more frequent stools, with no adverse effects on growth or infant behavior.
Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: A randomized clinical trial.
This randomized placebo-controlled clinical trial evaluated the effect of Bifidobacterium animalis subsp. lactis HN019-containing probiotic lozenges as an adjunct to scaling and root planing in 41 patients with chronic periodontitis. The Test group showed significant improvements in probing pocket depth, clinical attachment gain, reduction of periodontal pathogens, and lower proinflammatory cytokine levels compared to the Control group.
Safety of Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12-supplemented yogurt in healthy adults on antibiotics: a phase I safety study.
Phase I, double-blinded, randomized controlled study assessing the safety of Bifidobacterium animalis subsp lactis (BB-12)-supplemented yogurt in healthy adults on antibiotics. The study found no differences in adverse events between the control and BB-12 groups, indicating that BB-12-supplemented yogurt is safe and well tolerated.
Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product - a randomised study in healthy adults.
Randomised study in 12 healthy adults assessing the survival of Bifidobacterium animalis DN-173 010 after ingestion in a fermented product or lyophilised form. The study found that both forms survived transit with an average survival of 22% for the lyophilised form and 20% for the fermented product. No major modifications were observed in the dominant members of the faecal microbiota.
Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study.
Double-blind, cross-over RCT with 36 healthy women to assess the effect of Bifidobacterium animalis DN-173 010 on colonic transit time. The study found that B. animalis significantly shortened total and sigmoid colonic transit times compared to control, without affecting faecal weight, pH, bacterial mass, or bile acids.